UNSPSC 51332851: Fluphenazine enanthate

This classification denotes an antipsychotic agent with the molecular formula C29H38F3N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QSB34YF0W9, chemically known as sq 16,114 but more generally known as fluphenazine enantate, which bears US NIH Compound Identifier 3389. European Medicines Agency schedules Fluphenazine enantate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02231MIG. Most nations, for tariff and trade purposes, schedule fluphenazine enanthate under HS 29343090.

As of Q4 2014, FLUPHENAZINE ENANTHATE remains US FDA's Preferred Term for this commodity. Fluphenazine enanthate bears US NLM identifiers UMLS ID C0066682 and NCI Concept Code C65726. SMILES: CCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)C(F)(F)F.

UNSPSC 51332851 Fluphenazine enanthate (Commodity) shows minimal recent alignment with its nominal scope across state and local procurement records. The three most recent opportunities tagged to this code involve naloxone and drug deactivation systems, a direct-to-manufacturer pharmacy benefit initiative, and multi-source generic pharmaceuticals and OTC products — none of which are antipsychotic injectables or fluphenazine-specific procurement. The code's nominal product (fluphenazine enanthate, a long-acting injectable antipsychotic) does not appear in the scope of any recent state or local solicitation reviewed.

Recent activity under this code involves diverse issuing bodies: Seminole County, Florida (health and community support), the Texas Health and Human Services Commission (state pharmacy benefit planning), and the Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple jurisdictions including Oregon. The Seminole County IFB for naloxone and drug deactivation systems (IFB60459723LAS, due July 26, 2023) and the Minnesota MMCAP RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026) represent transactional procurement, while the Texas HHS RFI on direct-to-manufacturer prescription programs (HHS0017013, posted April 3, 2026) is exploratory market intelligence. The geographic spread spans Florida, Texas, and the upper Midwest, but the mismatch between the code's name and actual recent solicitation scope suggests this code may be a tagging error for broader pharmaceutical and community health acquisitions rather than a reliable indicator of fluphenazine enanthate demand in state and local markets.